May 2026
Cantoni Therapeutics on the road in May
In May 2026, Cantoni Therapeutics will be attending BioEquity Europe in Prague on 5 and 6 May and presenting preclinical data at the European Congress on Obesity in Istanbul from 12-15 May.
Connect with our CEO Annegret Van der Aa and Business Executive Philippe Alen on May 5 or 6 to learn more about our exciting program, developing small molecule inhibitors of NNMT as a novel and differentiated treatment for patients living with obesity and its cardiometabolic complications.
From May 12 to May 15, our CSO and Founder Matthijs van Haren will be presenting at the European Congress on Obesity in Istanbul. We look forward to showcase our preclinical work on the potential of NNMT inhibition in obesity, learn about the latest scientific developments in obesity treatments and connect with the scientific community.
If you are at ECO 2026, come find us at our poster PO1.073, displayed in the Poster Area at Level B5 of the congress center to learn more about Cantoni’s bisubstrate NNMT inhibitors as a novel, non-incretin-based, treatment option for obesity and its co-morbidities. The Poster Networking session is on Wednesday May 13 from 18.00 till 19.15 and the Poster viewing Times are on May 13 and 14 between 13.00 an 15.00.
Back to news overview